The DOI matches its Crossref record; 24 of the 28 references it cites were found in a registry or an index.
Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
Open accessAbstract
BACKGROUND: Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs for HCV infection have similar mechanisms of action and chemical structures to antiretrovirals for human immunodeficiency virus (HIV) infection. Generic antiretrovirals are currently manufactured at very low prices, to treat 10 million people with HIV/AIDS in developing countries. METHODS: Four HCV DAAs, currently either in phase 3 development or recent approval (daclatasvir, sofosbuvir, simeprevir, faldaprevir), and ribavirin were classified by chemical structure, molecular weight, total daily dose, and complexity of synthesis. The likely range of manufacturing costs per gram of DAA were then projected as formulated product cost, based upon treating a minimum of 1 million patients annually (to arrive at volume demand) combined with an analysis of the complexity of synthesis and a 40% margin for formulation. Projections were then compared with actual costs of antiretrovirals with similar structures. RESULTS: Minimum manufacturing costs of antiretrovirals were US$0.2-$2.1 per gram. The complexity of chemical synthesis for HCV DAAs was ranked from lowest to highest: ribavirin, daclatasvir, sofosbuvir, faldaprevir, and simeprevir. Predicted manufacturing costs (US dollars) for 12-week courses of HCV DAAs were $21-$63 for ribavirin, $10-$30 for daclatasvir, $68-$136 for sofosbuvir, $100-$210 for faldaprevir, and $130-$270 for simeprevir. CONCLUSIONS: Within the next 15 years, large-scale manufacture of 2 or 3 drug combinations of HCV DAAs is feasible, with minimum target prices of $100-$250 per 12-week treatment course. These low prices could make widespread access to HCV treatment in low- and middle-income countries a realistic goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our methodology for calculating drug EMPs has previously accurately predicted how low medication prices can go when they are produced generically [31]; however, this methodology is based on multiple assumptions.”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with cost-based pricing research similar to this, alongside advocacy groups and political will, treatment courses were brought down to <$100 per 12-week treatment course [31,40].”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“when direct-acting antivirals were developed for hepatitis C 10 years ago, courses were $84,000 per person ($1000/pill)”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515 · cited 1×
“Worldwide, 160–180 million people are antibody positive for Hepatitis C, with up to 500 000 HCV-related deaths per year [1, 2].”
BackgroundEvolving epidemiology of hepatitis C virus
Lavanchy, D. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03432.x · Cited by 1,318 · cited 1×
“Sources: Lavanchy [8]; Negro and Alberti [9].”
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090 · cited 2×
“Sofosbuvir + RBV POSITRON [15] (n = 207 + 71 placebo) IFN-ineligible 2 12 wk (n = 109) 93% (SVR-12)”
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“Daclatasvir has a straightforward synthesis with the cost-limiting intermediate being the substituted biphenyl compound shown (Table 5) [21, 22].”
BackgroundThe WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings
Gilks, C. F., Crowley, S., Ekpini, R., Gove, S., Perriens, J., Souteyrand, Y., Sutherland, D., Vitoria, M., Guerma, T., & De Cock, K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69158-7 · Cited by 689 · cited 1×
“proaches using tolerable, easy-to-administer regimens that are supportive of task shifting (care delivery by lesser trained health staff ) and good patient adherence, and could be facilitated by widespread access to oral, short-course DAA therapy in lowincome countries [29].”
BackgroundWitkowski, J. T., Robins, R. K., Sidwell, R. W., & Simon, L. N. (1972) · Journal of Medicinal Chemistry · doi:10.1021/jm00281a014 · Cited by 471 · cited 1×
“Analysis revealed that ribavirin has a relatively simple chemical synthesis [20].”
BackgroundLow-cost tools for diagnosing and monitoring HIV infection in low-resource settings
Wu, G., & Zaman, M. H. (2012) · Bulletin of the World Health Organization · doi:10.2471/blt.12.102780 · Cited by 190
The global health burden of hepatitis C virus infection
Negro, F., & Alberti, A. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02537.x · Cited by 181 · cited 1×
“Sources: Lavanchy [8]; Negro and Alberti [9].”
Moon, S., Jambert, E., Childs, M., & von Schoen-Angerer, T. (2011) · Globalization and Health · doi:10.1186/1744-8603-7-39 · Cited by 156
Research works printed but not linked: 5
- 2013, Journal of hepatology, 58, S22
- 2012, Clinical Infectious Diseases, 54, 145
- 2012, Hepatology (Baltimore, Md.), 56, 230A
- 2012, Hepatology (Baltimore, Md.), 56, 306A
- 2012, Hepatology (Baltimore, Md.), 56, 308A
Cited by
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19
Khalili, J. S., Zhu, H., Mak, N. S. A., Yan, Y., & Zhu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25798 · Cited by 359
“10 per gram.(29) An example of over‐the‐counter retail ribavirin cost in China is as follows: 1800mg of ribavirin retail price is approximately US $1.”
BackgroundChhatwal, J., Kanwal, F., Roberts, M. S., & Dunn, M. A. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1336 · Cited by 338
“lawmakers (13), the World Health Organization (14), and private payers (15), especially given that its manufacturing cost is $200 for 12-week treatment (16).”
BackgroundIyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K., & Hill, S. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002032 · Cited by 255
“A recent study estimated the cost of production of sofosbuvir to be US$68–US$136 for a 12-wk course of treatment based on the same manufacturing methods used in the large-scale generic production of HIV/AIDS medicines [12], and its findings have not been challenged.”
MethodBreakthroughs in hepatitis C research: from discovery to cure
Manns, M. P., & Maasoumy, B. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00608-8 · Cited by 231
APASL consensus statements and recommendation on treatment of hepatitis C
Omata, M., Kanda, T., Wei, L., Yu, M.-L., Chuang, W.-L., Ibrahim, A., Lesmana, C. R. A., Sollano, J., Kumar, M., Jindal, A., et al. (2016) · Hepatology International · doi:10.1007/s12072-016-9717-6 · Cited by 218
“However, the long duration of therapy (12–24 weeks) has raised concerns about adherence and cost [87].”
Background
Metadata
- Authors
- Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N.
- Affiliations
- University of Liverpool (GB)
- Howard University (US)
- Imperial College London (GB)
- University of Cape Town (ZA)
- Corresponding author
- Hill, A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-06
- Volume
- 58
- Issue
- 7
- Pages
- 928-936
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC3952605
- OpenAlex
- W2163848297
- Semantic Scholar
- 777a83aedceb6c84d3ff7d4176d38d6c2613d4a5
- Cited by
- 216
- References
- 28
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 8 · 2023: 10 · 2022: 9 · 2021: 5 · 2020: 15 · 2019: 14 · 2018: 22 · 2017: 26 · 2016: 34 · 2015: 43 · 2014: 24
- FWCI
- 23.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- hepatitis C, direct-acting antivirals, cost projections, daclatasvir, sofosbuvir, simeprevir, faldaprevir, ribavirin, generic drug production, treatment access, low- and middle-income countries, drug pricing
- MeSH terms
- Sofosbuvir, Simeprevir, Aminoisobutyric Acids, Antiviral Agents, Carbamates, Developing Countries, Drug Industry, Drug Therapy, Combination, Health Services Accessibility, Hepatitis C, Heterocyclic Compounds, 3-Ring, Humans, Imidazoles, Leucine, Oligopeptides, Proline, Pyrrolidines, Quinolines, Ribavirin, Sulfonamides, Thiazoles, Uridine Monophosphate, Valine, Hepacivirus, Anti-HIV Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries. https://app.cochat.ai/papers/10.1093/cid/ciu012
- The paper
- Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014). Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciu012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.